Ibandronate Sodium | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Ibandronate Sodium
HEALTH CANADA PATENTS

Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Contact Supplier

Jai Radhe Sales is your partner for all your sourcing needs.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

Contact Supplier

Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Ibandronate Sodium

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

35 API Suppliers, 14 USDMF, 3 CEP/COS, 1 JDMF, 7 EU WC, 24 KDMF, 5 NDC API, 20 Listed Suppliers, $ API Reference Price

35 API Suppliers
14 USDMF
3 CEP/COS
1 JDMF
7 EU WC
24 KDMF
5 NDC API
20 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

INTERMEDIATES

2 Intermediates Suppliers

2 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

201 FDF Dossiers, 21 FDA Orange Book, 134 Europe, 1 Australia, 10 South Africa, 35 Listed Dossiers

201 FDF Dossiers
21 FDA Orange Book
134 Europe
1 Australia
10 South Africa
35 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INTRAVENOUS - EQ 3MG BASE/3ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
INJECTABLE;INTRAVENOUS - EQ 3MG BASE/3ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Minakem, 1 Rochem International Inc, 4 SPI Pharma, 2 Seqens, 4 DKSH, 2 Jai Radhe Sales, 4 Faran Shimi Pharmaceutical, 1 Boai NKY Pharmaceuticals Ltd, 1 Chynops Pharma, 12 Gangwal Healthcare, 5 Nanjing Well Pharmaceutical, 1 ACG Worldwide, 5 Actylis, 1 Aeon Procare, 1 Alcedo Pharmachem, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 22 BASF, 1 Clariant, 10 Corel Pharma Chem, 5 DFE Pharma, 2 Finar, 8 Gangwal Chemicals, 7 Ideal Cures Pvt Ltd, 1 Ingredion Pharma Solutions, 31 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 13 Microlex e.U, 1 NEWEDGE Overseas, 2 Nomisma Healthcare, 3 Novo Excipients, 3 Pharmatrans-Sanaq, 4 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 19 Roquette, 7 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 2 The Dow Chemical Company, 1 Valens Pharmachem, 3 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

60 Fillers, Diluents & Binders, 55 Coating Systems & Additives, 31 Controlled & Modified Release, 27 Direct Compression, 23 Lubricants & Glidants, 21 Thickeners and Stabilizers, 20 Film Formers & Plasticizers, 20 Disintegrants & Superdisintegrants, 19 Granulation, 14 Topical, 13 Co-Processed Excipients, 13 Solubilizers, 12 Parenteral, 8 Taste Masking, 7 Chewable & Orodispersible Aids, 5 Empty Capsules, 5 API Stability Enhancers, 5 Coloring Agents, 5 Emulsifying Agents, 4 Rheology Modifiers, 4 Vegetarian Capsules, 1 Soft Gelatin, 1 Surfactant & Foaming Agents

60 Fillers, Diluents & Binders
55 Coating Systems & Additives
31 Controlled & Modified Release
27 Direct Compression
23 Lubricants & Glidants
21 Thickeners and Stabilizers
20 Film Formers & Plasticizers
20 Disintegrants & Superdisintegrants
19 Granulation
14 Topical
13 Co-Processed Excipients
13 Solubilizers
12 Parenteral
8 Taste Masking
7 Chewable & Orodispersible Aids
5 Empty Capsules
5 API Stability Enhancers
5 Coloring Agents
5 Emulsifying Agents
4 Rheology Modifiers
4 Vegetarian Capsules
1 Soft Gelatin
1 Surfactant & Foaming Agents

DIGITAL CONTENT

6 NEWS #PharmaBuzz

6 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

112 Finished Drug Prices

112 Finished Drug Prices

MARKET PLACE

6 APIs, 3 FDF Dossiers

6 APIs
3 FDF Dossiers

PATENTS & EXCLUSIVITIES

2 Health Canada Patents

2 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 USP, 2 Others

2 USP
2 Others

$ API Ref.Price (USD/KG) : 915 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

2 All

01 1Gowling Lafleur Henderson LLP

02 1Blank

filter Patent Reset all filters

2 All

01 11296739

02 12346662

filter Product Reset all filters

2 All

01 1Ibandronate

02 1Blank

filter Dosage Reset all filters

2 All

01 1Tablet

02 1Blank

filter Exp Date Reset all filters

2 All

01 12009-03-03

02 12019-10-01

Product Main Page

01

Gowling Lafleur Henderson LLP

Ibandronate Sodium

Fi Europe 2024

Not Confirmed

Gowling Lafleur Henderson LLP

Canada

Fi Europe 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2019-10-01

Date Granted : 2006-05-09

Ibandronate Sodium

Brand Name : BONVIVA

Patent Number : 2346662

Filing Date : 1999-10-01

Strength per Unit : 2.5 mg

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2019-10-01

Date Granted : 2006-05-09

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

Ibandronate Sodium

Fi Europe 2024

Not Confirmed

Country

Fi Europe 2024

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2009-03-03

Date Granted :

Ibandronate Sodium

Brand Name :

Patent Number : 1296739

Filing Date :

Strength per Unit :

Dosage Form :

Human Or VET :

Route of Administration :

Patent Expiration Date : 2009-03-03

Date Granted :

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?